A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

被引：7
|
作者：
Puglisi, Fabio [1 ]
Bisagni, Giancarlo [2 ]
Ciccarese, Mariangela [3 ]
Fontanella, Caterina [1 ]
Gamucci, Teresa [4 ]
Leo, Luigi [5 ]
Molino, Annamaria [6 ]
Silva, Rosa Rita [7 ]
Marchetti, Paolo [8 ,9 ]
机构：
[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy
[2] Azienda Osped ASMN, Dept Oncol, Oncol Unit, Ist Ricovero & Cura Carattere Sci, Reggio Emilia, Italy
[3] Vito Fazzi Hosp, Dept Med Oncol, Lecce, Italy
[4] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[5] Azienda Osped Colli, Oncol Unit, Naples, Italy
[6] Univ Verona, Verona, Italy
[7] ASUR Marche AV2 Fabriano, Med Oncol Unit, Fabriano, Italy
[8] Sapienza Univ Rome, Med Oncol, St Andrea Hosp, Rome, Italy
[9] IDI IRCCS, Rome, Italy
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 22期
关键词：
angiogenesis; bevacizumab; breast cancer; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; CONTAINING THERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; PLUS BEVACIZUMAB; TARGETED THERAPIES; AND/OR BEVACIZUMAB; LOCALLY RECURRENT; CLINICAL-PRACTICE;
D O I：
10.2217/fon-2016-0295
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.
引用
收藏
页码：2589 / 2602
页数：14
相关论文
共 50 条
  • [41] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Christopher Lobo
    Gilberto Lopes
    Odalys Baez
    Aurelio Castrellon
    Annapoorna Ferrell
    Connie Higgins
    Erin Hurley
    Judith Hurley
    Isildinha Reis
    Stephen Richman
    Pearl Seo
    Orlando Silva
    Joyce Slingerland
    Keleni Tukia
    Catherine Welsh
    Stefan Glück
    Breast Cancer Research and Treatment, 2010, 123 : 427 - 435
  • [42] Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
    Al Mahmasani, Layal
    Amhaz, Ghid
    Abou Zeidane, Reine
    Chamseddine, Nathalie
    Hatab, Taha
    Sabbagh, Saad
    Charafeddine, Maya
    Assi, Hazem I.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] Bevacizumab in first-line treatment of metastatic breast cancer
    Miles, David
    DRUGS, 2007, 67 (12) : 1800 - 1800
  • [44] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Alessandra Fabi
    Michelangelo Russillo
    Gianluigi Ferretti
    Giulio Metro
    Cecilia Nisticò
    Paola Papaldo
    Ferdinando De Vita
    Giuliana D’Auria
    Antonello Vidiri
    Diana Giannarelli
    Francesco Cognetti
    BMC Cancer, 12
  • [45] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Katherine F. Croom
    Sohita Dhillon
    Drugs, 2011, 71 : 2213 - 2229
  • [46] Bevacizumab in the first-line treatment of metastatic breast cancer
    Cameron, David
    EJC SUPPLEMENTS, 2008, 6 (06): : 21 - 28
  • [47] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Fabi, Alessandra
    Russillo, Michelangelo
    Ferretti, Gianluigi
    Metro, Giulio
    Nistico, Cecilia
    Papaldo, Paola
    De Vita, Ferdinando
    D'Auria, Giuliana
    Vidiri, Antonello
    Giannarelli, Diana
    Cognetti, Francesco
    BMC CANCER, 2012, 12
  • [48] Choice of primary endpoints in first-line phase III trials of HER2-negative or HER2-unknown metastatic breast cancer (MBC).
    Kuemmel, Sherko
    Mueller, Volkmar
    Lux, Michael P.
    Weyer, Geerd
    Pintoffl, Jan P.
    Jackisch, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study
    Andreis, D.
    Scandurra, G.
    Santini, D.
    Gucciardino, C.
    La Verde, N. M.
    Girelli, S.
    Alabiso, I.
    Saetta, A.
    Atzori, F.
    Collova, E.
    Ferzi, A.
    Gori, S.
    Lipari, H.
    Saggia, C.
    Marcon, I.
    Generali, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL, BEVACIZUMAB, AND GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Gluck, S.
    Lobo, C.
    Hurley, J.
    Lopes, G.
    Reis, I.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    Tukia, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 69
12345